In a preclinical scenario from an orthotopic SCLC model with extensive disease, Sakamoto et al. showed that treatment with the Met inhibitor PHA665752 inhibited motility and the invasion of SCLC cells harboring high HGF expression [86]. Here, MET is linked to small cell lung carcinoma.